Levofloxacin

SKU: orb1300652

Description

Levofloxacin

Research Area

Infectious Disease & Virology, Molecular Biology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 100986-85-4
• MW: 361.37
• Purity: 99.93% (May vary between batches)
• Formula: C₁₈H₂₀FN₃O₄
• SMILES: O=C1C=2C3=C(C(=C(F)C2)N4CCN(C)CC4)OC[C@H](C)N3C=C1C(O)=O
• Target: Antibiotic,Topoisomerase,Antibacterial
• Solubility: H2O:9 mg/mL (24.91 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (2.77 mM);DMSO:42.5 mg/mL (117.61 mM);Ethanol:2 mg/mL (5.53 mM)

Bioactivity

• Target IC50:
  P-gp (Caco-2 cells):1644 μM|ΔTolC E.coli:0.016 μg/mL (MIC)|K562 cells proliferation:10.4 μM
• In Vivo:
  METHODS: To study in vivo antimicrobial activity, Levofloxacin (100 mg/kg) and Imipenem (100 mg/kg) were administered intraperitoneally four times at 3 h intervals in the Acinetobacter baumannii pneumonia mouse model. RESULTS: For Levofloxacin-sensitive strains, Levofloxacin and Imipenem were less bactericidal, with a slight reduction in lung bacterial counts compared to values at the start of treatment. The combination of Levofloxacin and Imipenem did not increase bactericidal activity. All regimens tested significantly reduced mortality compared to controls.
  Read more...
• In Vitro:
  METHODS: Bladder cell lines SV-HUC-1 and T24 were treated with Levofloxacin (25-800 µg/mL) for 24-48 h. Cell viability was measured by MTT assay. RESULTS: Levofloxacin is cytotoxic in a dose- and time-dependent manner. METHODS: IL-1β-stimulated inflammatory FLS cells were treated with Levofloxacin (14-224 µM) for 24 h, and gene expression levels were measured by RT-qPCR. RESULTS: When IL-1β-stimulated inflammatory FLS were treated with Levofloxacin for 24 h, the mRNA levels of MMP-1 and MMP-3 were increased in a concentration-dependent manner, and the mRNA expression level of TIMP-1 was also increased accordingly. In addition, the expression of pro-inflammatory cytokines IL-6 and COX-2 decreased in a concentration-dependent manner, while PGE2 did not show any significant changes. In addition, the expression levels of Caspase-3 and Caspase-8 increased in a concentration-dependent manner.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

DNA/RNA Synthesis, DNA gyrase, Cravit, chronic periodontitis, Bacterial, BK Viremia, Antibiotic, airway inflammation, (-)-Ofloxacin, Inhibitor, inhibit, Orthopoxvirus, Ofloxacin, Levaquin, Levofloxacin, Fluoroquinolone, Topo II, Topo IV, Topoisomerase, Tavanic

Compound Identifiers

PubChem CID

149096